Obesity

A new study has found a link between the rollout of high-speed internet services and a rise in obesity rates. The researchers who conducted the study attribute the increase to the effect of high-speed internet access on physical activity and eating habits.

Game-changing GLP-1 agonist drugs are a step closer to being available in oral pill form, with AstraZeneca revealing "encouraging data" from the Phase I safety and tolerability trial of its once-daily obesity and diabetes drug AZD5004.

A new oral nanotherapy works directly on the small intestine, reducing its ability to absorb fat from the food we eat, according to a new study. If it proves effective in humans, it has huge potential as a treatment for diet-related obesity.

In the first study of its kind, excess abdominal fat has been associated with chronic pain, but the good news is that losing weight that can reduce waistlines could help relieve widespread musculoskeletal conditions and greatly improve quality of life.

The race is on to deliver the first once-a-day weight-loss pill that would be both cheaper and less invasive than the current injectable drugs, with strong results from Terns following those from competitors Eli Lilly, Pfizer, Roche and Structure.

While being a night owl has a certain cachet, a new study shows that staying up into the wee hours can be downright dangerous. The late-night lifestyle was shown to dramatically raise diabetes risk and cause several other health-damaging effects.

Not all fiber is created equal, and one particular type – which is most highly concentrated in common breakfast oats – may trigger the same beneficial metabolic functions that GLP-1 agonists like Ozempic do, without the price tag or side-effects.

A compound that occurs in mature olives and olive oil can regulate glucose and ramp up weight loss in rapid time, mimicking the effects of existing medication. This opens the door for developing safe, natural treatments for obesity and type 2 diabetes.

The popular class of antidiabetic and weight loss drugs known as GLP-1RAs, which includes Ozempic and Wegovy, has been found to significantly reduce the risk of 10 out of 13 obesity-associated cancers in type 2 diabetics, according to new research.

Being prescribed semaglutide for diabetes or weight management is associated with an increased risk, up to seven times, of developing a relatively rare form of untreatable blindness, sometimes referred to as an 'eye stroke,' a new study has found.

By suppressing one protein, stores of white fat can switch to calorie-burning beige fat, in a feat that so far has eluded scientists working in this field. This means long-lasting weight loss without the brain-gut side effects of existing obesity drugs.

Intermittent fasting (IF) is currently one of the most popular health and fitness trends. But, as with anything popular, it has its nay-sayers. So, we looked at the science that backs up what these kinds of diets can do and busted some myths in the process.